Skip to content
OpenCapital
Get started

Aurinia Pharmaceuticals AUPH Cash & Equivalents

Cash & Equivalents at other companies

Rogers Corporation logo
Rogers CorporationROG
$195.8M+11.5%
Vera Therapeutics logo
Vera TherapeuticsVERA
$114.35M+108%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$175M+37.8%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$113.6M+43.9%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$882.02M+62.5%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$189.95M+20.9%

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.3B+78.5%
Enterprise value$2.34B+78.3%
P/E7.7×-24.6×
P/S7.7×+2.5×

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's cash & equivalents?
Aurinia Pharmaceuticals (AUPH) reported cash & equivalents of $41.01M in Q1 2026.
How has Aurinia Pharmaceuticals's cash & equivalents changed year-over-year?
Aurinia Pharmaceuticals's cash & equivalents decreased by 38.3% year-over-year, from $66.43M to $41.01M.
What is the long-term trend for Aurinia Pharmaceuticals's cash & equivalents?
Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's cash & equivalents has grown at a -21.7% compound annual growth rate (CAGR), from $272.35M to $80.21M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.